autologous immune cells
Cell therapyexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 27, 2017 (NCT03085966)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- leukocytesImmunity, active
leukocytes immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous immune cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07260058 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2025 | Dalian Medical University, Government of China |
| NCT05438342 | N/A | Nov 1, 2021 | Duke University, Fudan University, Ningxia Medical University |
| NCT03085966 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2017 | Cellular Biomedicine Group Ltd., Fudan University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 2 | 0 | 2 | 2017 |
| Cellular Biomedicine Group Ltd. | For profit | 1 | 1 | 1 | 2017 |
| Dalian Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| Ningxia Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1